IL36B

Across TCGA pan-cancer cohorts, IL36B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL36B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IL36B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL36B expression acts as an unfavorable survival marker.

OV, HNSC, and CESC are the cancer types where IL36B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.662	0.841	.046	8	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
CESC	DFS	Median	All	0.118	0.544	.048	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL36B–OV (OS)

Open the OV breakdown →